Skip to main content
. 2019 Jan 15;316(5):E749–E772. doi: 10.1152/ajpendo.00343.2018

Table 3.

Femoral cortical architecture from WT and Nmp4−/− mice treated with vehicle, raloxifene, parathyroid hormone, and parathyroid hormone + raloxifene

Marrow Area, mm2 Cortical Area, mm2 Cortical Thickness, mm Periosteal BS, mm Endocortical BS, mm
Group
    WT VEH 0.940 ± 0.049 0.829 ± 0.052 0.204 ± 0.008 5.393 ± 0.139 4.140 ± 0.114
 Nmp4−/− VEH 0.913 ± 0.049 0.838 ± 0.039 0.209 ± 0.009 5.353 ± 0.090 4.078 ± 0.106
    WT RAL 0.860 ± 0.022 0.867 ± 0.037 0.216 ± 0.006 5.344 ± 0.090 4.019 ± 0.095
 Nmp4−/− RAL 0.879 ± 0.039 0.865 ± 0.047 0.218 ± 0.010 5.332 ± 0.111 4.004 ± 0.103
    WT PTH 0.969 ± 0.048 0.949 ± 0.078 0.221 ± 0.005 5.617 ± 0.196 4.213 ± 0.108
 Nmp4−/− PTH 0.931 ± 0.064 0.951 ± 0.062 0.226 ± 0.007 5.564 ± 0.087 4.142 ± 0.116
    WT PTH + RAL 0.892 ± 0.043 0.995 ± 0.070 0.239 ± 0.007 5.552 ± 0.152 4.084 ± 0.106
 Nmp4−/− PTH + RAL 0.852 ± 0.029 1.00 ± 0.067 0.249 ± 0.013 5.478 ± 0.081 3.978 ± 0.038
Two-way ANOVA genoptype G: P = 0.0295 G: P = 0.3420 G: P = 0.008 G: P = 0.0780 G: P = 0.0034
WT: 0.915a Nmp4−/−: 0.225a WT: 4.11a
Nmp4−/−: 0.894b WT: 0.220b Nmp4−/−: 4.05b
Two-way ANOVA treatment T: P < 0.0001 T: P < 0.0001 T: P < 0.0001 T: P < 0.0001 T: P < 0.0001
P: 0.950a P + R: 0.990a P + R: 0.244a P: 5.59a P: 4.18a
V: 0.927a P: 0.954a P: 0.223b P + R: 5.52a V: 4.11a
P + R: 0.872b R: 0.866b R: 0.217b V: 5.37b P + R: 4.03b
R: 0.869b V: 0.833b V: 0.206 c R: 5.34b R: 4.01b
Two-way ANOVA G × T G × T: P = 0.1459 G × T: P = 0.88 G × T: P = 0.4695 G × T: P = 0.8513 G × T: P = 0.4973
Iap, mm4 Iml, mm4 Imax, mm4 Imin, mm4 TMD, g/cm3 HA
Group
    WT VEH 0.228 ± 0.029 0.144 ± 0.015 0.237 ± 0.029 0.135 ± 0.015 1.29 ± 0.03
 Nmp4−/− VEH 0.219 ± 0.008 0.143 ± 0.012 0.224 ± 0.013 0.137 ± 0.012 0.89 ± 0.01
    WT RAL 0.231 ± 0.016 0.144 ± 0.012 0.237 ± 0.016 0.138 ± 0.010 1.27 ± 0.01
 Nmp4−/− RAL 0.228 ± 0.021 0.142 ± 0.012 0.235 ± 0.022 0.138 ± 0.014 0.89 ± 0.01
    WT PTH 0.285 ± 0.048 0.179 ± 0.022 0.297 ± 0.053 0.167 ± 0.019 1.28 ± 0.03
 Nmp4−/− PTH 0.279 ± 0.025 0.173 ± 0.007 0.281 ± 0.022 0.169 ± 0.010 0.89 ± 0.01
    WT PTH + RAL 0.291 ± 0.044 0.173 ± 0.016 0.302 ± 0.043 0.162 ± 0.016 1.28 ± 0.02
 Nmp4−/− PTH + RAL 0.270 ± 0.030 0.174 ± 0.019 0.276 ± 0.031 0.167 ± 0.017 0.88 ± 0.01
Two-way ANOVA genotype G: P = 0.1257 G: P = 0.5224 G: P = 0.0325 G: P = 0.4557 G: P < 0.0001
WT 0.268a WT 1.28a
Nmp4−/−: 0.254b Nmp4−/−: 0.886b
Two-way ANOVA treatment T: P < 0.0001 T: P < 0.0001 T: P < 0.0001 T: P < 0.0001 T: P = 0.2325
P: 0.282a P A 0.176a P + R 0.289a P: 0.168a
P + R: 0.281a P + R: 0.173a P: 0.289a P + R: 0.165a
R: 0.230b V: 0.143b R: 0.236b R: 0.138b
V: 0.223b R: 0.143b V: 0.230b V: 0.136b
Two-way ANOVA G × T G × T: P = 0.7276 G × T: P = 0.9050 G × T: P = 0.6236 G × T: P = 0.9269 G × T: P = 0.3597

Data represent average ± SD; n = 7–15 mice/group. Nmp4, nuclear matrix protein 4; WT, wild type; V/VEH, vehicle; R/RAL, raloxifene; P/PTH, parathyroid hormone; P/PTH + R/RAL, and parathyroid hormone + raloxifene; HA hydroxyapatite; Iap moment of inertia about the femoral anterior–posterior length axis; Imax maximum moment of inertia; Imin minimum moment of inertia; Iml moment of inertia about the femoral medial-lateral axis; TMD tissue mineral density. Statistical analyses were performed using two-way ANOVA tests setting genotype (G) and treatment (T) as the independent variables. Statistical significance was set at P ≤ 0.05. The statistical results list the cohorts by genotype, treatment, and genotype × treatment. See text for explanation of results.

a b cCohorts not connected by the same letter are statistically different; the average value of the specific parameter precedes the letter.